What Breckenridge Pharmaceutical does

Breckenridge Pharmaceutical, Inc. is a privately held U.S. generic pharmaceutical company founded in 1983 and headquartered in Berlin/Berkeley Heights, Connecticut. It operates as the U.S. subsidiary of Towa Pharmaceutical (Osaka, Japan), distributing cost-effective AB-rated generic equivalents of branded reference drugs through three formal business lines: specialty (oncology and immunosuppression generics), hospital (sterile injectables for anesthesia, critical care, and emergency medicine), and retail (broad oral-solid and consumer health portfolio including prescription generics, medical foods, prenatal and dietary supplements, and non-prescription products). The company does not own primary manufacturing assets; instead it commercializes products developed and manufactured through affiliated Towa International facilities (notably a Martorelles, Spain plant with annual capacity exceeding 6 billion doses) and through strategic development partners including NATCO Pharma, Maiva Pharma, Medichem Solutions, Centaur Pharmaceuticals, and Andersen Pharma Global.

The portfolio spans more than 20 marketed molecules across antidepressants (Duloxetine, Desvenlafaxine), antiepileptics (Lacosamide, Oxcarbazepine, Levetiracetam), antipsychotics (Asenapine), oncology (Everolimus, Anastrozole, Exemestane, Pomalidomide), immunosuppressants, antifungals, migraine (Rizatriptan), insomnia (Zolpidem ER), and the recent Tofacitinib launch (generic Xeljanz). Distribution occurs through retail and mail-order pharmacies, specialty pharmacies and clinics, and a newly developed direct U.S. hospital channel, with global reach provided through Towa2B to more than 40 countries. Revenue mechanics are those of a traditional specialty/retail generic distributor: AB-rated product sales negotiated through pharmacy benefit managers, insurers, and government payors, augmented by copay assistance programs for select specialty launches such as Pomalidomide.

Recent strategic actions include an aggressive 2025–2026 launch cadence (Pomalidomide, Tofacitinib, Milnacipran, Everolimus TFOS, Dehydrated Alcohol Injection), the formation of two anchor hospital-channel partnerships with Maiva (March 2026) and Medichem (February 2026), and capture of 180-day shared exclusivity on Pomalidomide against a $3.2 billion reference drug market. Offsetting signals include a Class II Duloxetine recall covering approximately 370,000 bottles, active patent litigation with Hetero USA, and a Cigna antitrust suit referencing reverse payments, all of which frame Breckenridge as an actively executing, parent-backed mid-sized U.S. generic player positioned in a strong-growth phase.

Name

Breckenridge Pharmaceutical

Legal name

Breckenridge Pharmaceutical, Inc.

Website

https://bpirx.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

51–100 employees

Short description

Breckenridge Pharmaceutical is a privately held U.S. generic pharmaceutical distributor and subsidiary of Towa Pharmaceutical that develops and commercializes AB-rated generic equivalents across specialty, hospital, and retail channels, primarily through partner-based manufacturing with NATCO, Maiva, Medichem, and Centaur.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Generic Hospital & Institutional Products (HLAIABAL), Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Prescription generics
• Sterile injectables
• Medical foods
• Oncology generics

Headquarters

HQ city

Berkeley Heights

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Generic Pharmaceutical Sales: Breckenridge Pharmaceutical generates revenue by developing, manufacturing (through partners), and distributing generic pharmaceutical products in the U.S. market. Products span prescription generics, medical foods, prenatal & dietary supplements, and non-prescription products sold through retail pharmacies, specialty pharmacies, clinics, and hospital channels.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Breckenridge Pharmaceutical, Inc. develops, manufactures (through partner facilities), and distributes cost-effective AB-rated generic pharmaceutical products in the U.S. market. The company operates across three patient-focused business lines—specialty, hospital, and retail—offering prescription generics, medical foods, prenatal and dietary supplements, and non-prescription products spanning oncology, immunosuppression, neurology, psychiatry, pain management, and hospital-based injectables.

Product overview

Breckenridge Pharmaceutical, Inc. is a U.S. subsidiary of Towa Pharmaceutical (Osaka, Japan) that develops, manufactures, and distributes cost-effective generic pharmaceuticals throughout the United States. The company operates across three patient-focused business lines: specialty, hospital, and retail. Its product portfolio spans prescription generics across multiple therapeutic categories including antidepressants (Duloxetine, Desvenlafaxine, Alprazolam), antiepileptics (Lacosamide, Oxcarbazepine, Levetiracetam), antipsychotics (Asenapine, Clobazam), oncology treatments (Everolimus, Exemestane, Anastrozole, Pomalidomide), immunosuppressants (Everolimus for organ transplant), migraine treatments (Rizatriptan), dermatology (Terbinafine), and insomnia treatments (Zolpidem). The company also offers medical foods including Ferrex 150 Forte Plus, Folbee, L-Methylfolate products, and Metafolbic formulations. Products are developed through affiliated R&D centers and strategic partnerships globally, with manufacturing through parent company Towa International facilities in Spain and partnerships with companies like Natco Pharma (India), Centaur Pharmaceuticals, Maiva Pharma, and Medichem Solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Tofacitinib Tablets Generic equivalent of Pfizer's Xeljanz for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Manufactured at Towa's facility in Martorelles, Spain.
• Milnacipran HCl Tablets Generic equivalent of AbbVie's Savella for fibromyalgia management. Available in 12.5mg, 25mg, 50mg, and 100mg strengths, manufactured by Centaur Pharmaceuticals.
• Pomalidomide Capsules Generic version of Celgene's Pomalyst for treating multiple myeloma and Kaposi sarcoma. Available in 1mg, 2mg, 3mg, and 4mg strengths, developed in collaboration with NATCO Pharma.
• Everolimus Tablets 1mg (Zortress generic) Generic version of Novartis' Zortress, an immunosuppressant for organ transplant rejection prevention. Available in 0.5mg, 0.75mg, and 1mg strengths. Developed with Natco Pharma.
• Dehydrated Alcohol Injection, USP Generic version of Belcher Pharmaceuticals' Ablysinol. 5mL single-dose vials containing ≥99% by volume ethyl alcohol, indicated for induction of controlled cardiac septal infarction in HOCM patients. Developed with Andersen Pharma Global.
• Everolimus Tablets for Oral Suspension Generic version of AFINITOR DISPERZ for treating tuberous sclerosis complex in patients one year and older. Available in 2mg, 3mg, and 5mg dosages. ANDA held by partner Natco Pharma.
• Alprazolam Tablets Generic version of Pfizer's Xanax, an anxiolytic medication. Available in 0.25mg, 0.5mg, 1mg, and 2mg strengths. AB-rated generic with Schedule CIV classification.
• Anastrozole Tablets Generic version of AstraZeneca's Arimidex, an aromatase inhibitor for breast cancer treatment. White, round, film-coated tablet in 1mg strength.
• Asenapine Sublingual Tablets Generic version of Merck's Saphris, an atypical antipsychotic. Available in 2.5mg, 5mg, and 10mg strengths. White, round uncoated tablets for sublingual administration.
• Azelastine Hydrochloride Nasal Solution Generic version of Meda's Astelin nasal spray. 0.1% solution delivering 137 mcg azelastine per spray in 30mL HDPE bottle with 200 metered sprays.
• Clobazam Tablets Generic version of Lundbeck's Onfi, an anticonvulsant/antiepileptic. Available in 10mg and 20mg strengths. White to off-white oval tablets with functional score.
• Desvenlafaxine Extended-Release Tablets Generic version of Pfizer's Pristiq, an SNRI antidepressant. Available in 25mg, 50mg, and 100mg strengths. Colored round biconvex tablets.
• Duloxetine Delayed-Release Capsules Generic version of Eli Lilly's Cymbalta, an SNRI antidepressant. Available in 20mg, 30mg, 40mg, and 60mg strengths. Color-coded capsules for different dosages.
• Everolimus Tablets (Afinitor generic) Generic version of Novartis' Afinitor, an mTOR inhibitor for oncology and transplant rejection prevention. Available in 2.5mg, 5mg, 7.5mg, and 10mg strengths.
• Exemestane Tablets Generic version of Pfizer's Aromasin, an aromatase inhibitor for breast cancer. 25mg white colored round biconvex film-coated tablets.
• Lacosamide Tablets Generic version of UCB's Vimpat, an anticonvulsant/antiepileptic. Available in 50mg, 100mg, 150mg, and 200mg strengths. Color-coded oval film-coated tablets (CV classification).
• Levetiracetam Solution Generic version of UCB's Keppra, an anticonvulsant/antiepileptic. 100mg/mL oral solution in 16oz bottles. Clear colorless to light yellow grape-flavored liquid.
• Oxcarbazepine Tablets Generic version of Novartis' Trileptal, an anticonvulsant/antiepileptic. Available in 150mg, 300mg, and 600mg strengths. Beige film-coated modified oval scored tablets.
• Rivastigmine Transdermal System Generic version of Novartis' Exelon, a cholinesterase inhibitor for Alzheimer's disease. Available in 4.6mg/24hr, 9.5mg/24hr, and 13.3mg/24hr patch strengths.
• Rizatriptan Benzoate Tablets Generic version of Merck's Maxalt, a triptan for migraine relief. Available in 5mg and 10mg strengths. Light pink to pink-colored capsule-shaped biconvex uncoated tablets.
• Terbinafine Tablets Generic version of Novartis' Lamisil, an antifungal medication. 250mg white oblong unscored tablets in 72-count bottles.
• Zolpidem Tartrate Extended-Release Tablets Generic version of Sanofi's Ambien CR, a sedative-hypnotic for insomnia. Available in 6.25mg and 12.5mg strengths. Two-layer coated tablets (CIV classification).
• Ferrex 150 Forte Plus Capsules Medical food for iron deficiency conditions. Niferex-150 forte formulation. White/red capsule with B798 imprint. Covered by US Patents 6,716,814, 8,007,846, and 8,425,956.
• Folbee Tablets Medical food supplement (generic for Foltx original strength). Oval natural orangish colored tablet with B084 imprint.
• L-Methylfolate Forte Capsules Medical food supplement (generic for Deplin). Available in 7mg and 15mg strengths. Color-coded capsules.
• Metafolbic Plus Caplets Medical food supplement (generic for Cerefolin NAC). Oval coated blue colored caplets with LMF6 imprint. Covered by US Patent 7,709,460.

Quantifiable outcome

• 180 days of shared exclusivity for Pomalidomide generic launch (March 2026)
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered minor and core.

• Centaur Pharmaceuticals Pvt. Ltd.minorStrategic or Co-development Partner · 19 March 2026Breckenridge launched Milnacipran HCl Tablets, a generic equivalent of Savella, manufactured by Centaur Pharmaceuticals Pvt. Ltd. The product is distributed through retail and mail order pharmacies in four dosage strengths (12.5mg, 25mg, 50mg, 100mg) for fibromyalgia management.
• Maiva Pharma Pvt. Ltd.coreStrategic or Co-development Partner · 11 March 2026Breckenridge Pharmaceutical entered a strategic partnership with Maiva Pharma Pvt. Ltd. to supply sterile injectable products primarily to U.S. hospitals and clinics. Maiva serves as a key manufacturing partner for several injectable products, leveraging its three decades of sterile manufacturing expertise and two facilities in Bengaluru, India. The collaboration strengthens Breckenridge's position in the U.S. hospital market and supports its evolution into three patient-focused business lines: specialty, hospital, and retail.
• NATCO Pharma LimitedcoreStrategic or Co-development Partner · 2 March 2026Breckenridge launched Pomalidomide Capsules, a generic version of Pomalyst, in collaboration with NATCO Pharma Limited of India. The product is available in 1mg, 2mg, 3mg, and 4mg strengths through specialty pharmacies and clinics for treating multiple myeloma and Kaposi sarcoma. NATCO and Breckenridge have an established partnership spanning multiple generic launches including Everolimus tablets (Zortress andAfinitor DISPERZ) and Pomalidomide, with NATCO believing it holds 180 days of shared exclusivity for the Pomalidomide generic.
• Medichem Solutions S.L.coreStrategic or Co-development Partner · 5 February 2026Breckenridge announced a strategic collaboration with Medichem Solutions S.L. encompassing a basket of injectable products used in anesthesia, critical care, and emergency medicine, expanding its U.S. hospital channel presence. The partnership involves products manufactured at Medichem's new state-of-the-art sterile fill-and-finish facility in Asturias, Spain. This collaboration represents another milestone in Breckenridge's strategic evolution into three distinct business lines: specialty, hospital, and retail.
• Andersen Pharma GlobalminorStrategic or Co-development Partner · 24 June 2025Breckenridge received final FDA approval for Dehydrated Alcohol Injection, USP, a generic version of Ablysinol by Belcher Pharmaceuticals, developed in partnership with Andersen Pharma Global. The 5mL single-dose vials contain ≥99% by volume ethyl alcohol and are indicated for induction of controlled cardiac septal infarction. The launch positions Breckenridge as one of the first companies in the U.S. market to offer a generic alternative to Ablysinol, aligning with its strategic plan to expand presence in the institutional healthcare channel.

Scale indicators5 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• Amneal Pharmaceuticals: Amneal is a U.S.-focused generic and specialty pharmaceutical company that develops, manufactures, and distributes AB-rated generic equivalents across a broad therapeutic range. Its portfolio breadth, specialty/injectables focus, and tiered distribution strategy closely mirror Breckenridge's three business lines.
• Zydus Pharmaceuticals (USA): Zydus USA is the U.S. subsidiary of India's Zydus Cadila, offering generic prescription, specialty, and injectable products distributed through retail, mail order, and institutional channels. Like Breckenridge, it operates through Indian parent manufacturing and supplies a similarly broad generic portfolio.
• Aurobindo Pharma USA: Aurobindo USA is a top-10 U.S. generic supplier with a portfolio spanning oral solids, injectables, and specialty products. Its parent-driven manufacturing model and broad retail/hospital distribution directly parallel Breckenridge's strategic positioning.
• Hikma Pharmaceuticals: Hikma is a multinational generic pharmaceutical company with strong U.S. hospital and injectable franchises. Its specialty/generic product breadth and emphasis on hospital injectables are directly comparable to Breckenridge's three-line strategy.
• Apotex Corp. Apotex is a Canadian-headquartered generic pharmaceutical manufacturer with a substantial U.S. presence offering prescription generics, injectables, and specialty products. Its portfolio composition and channel strategy overlap significantly with Breckenridge's.
• Endo International: Endo operates a generic pharmaceuticals segment (Par Health) alongside specialty and sterile injectables, covering retail, hospital, and specialty channels. Its diversified generic/specialty footprint is a comparable analog to Breckenridge's three business lines.
• Alvogen: Alvogen is a privately-held U.S./EMEA generic pharmaceutical company focused on specialty, retail, and hospital generics. Its privately-held status and partnership-driven growth model closely mirror Breckenridge's profile.
• Lupin Pharmaceuticals: Lupin is an India-based generic pharmaceutical company with significant U.S. operations covering oral solids, specialty, and complex injectables. Its product portfolio and channel distribution patterns are closely comparable to Breckenridge's.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a U.S. portfolio spanning nearly every therapeutic category, including specialty and hospital injectables. It is a broad incumbent against whom Breckenridge competes for retail and specialty shelf space.
• Sandoz (Novartis): Sandoz is a global leader in generics and biosimilars, with a substantial U.S. retail and hospital presence. As a broad incumbent player, it competes directly with Breckenridge across multiple generic product categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breckenridge Pharmaceutical